Avantor, Inc.
AVTRHealthcareNASDAQMedical Instruments & Supplies · Last scanned Jul 15, 2026
Scan Results
Daily timeframeAvantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the. At a $7.71B market cap, Avantor, Inc. ranks as a mid-cap company within healthcare. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips.
Market Cap
$7.71B
Beta
0.94
P/E (TTM)
—
P/E (Fwd)
13.26
EPS (TTM)
$-0.87
EPS (Fwd)
$0.85
ROE
-9.4%
ROA
2.8%
Cash
$279.3M
Total Debt
$3.82B
Free CF
$489.4M
52W Change
-17.6%
Annual Financials
Cash vs Debt
Avantor, Inc. carries $3.82B in total debt against $279.3M in cash reserves — debt is roughly 13.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $489.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -9.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.8% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $7.51B (2022) to $6.55B (2025), a 13% decline worth watching.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Avantor, Inc.'s trajectory.